| Biosimilars in developed economies: overview, status, and regulatory considerations AS Rathore, A Bhargava Regulatory Toxicology and Pharmacology 110, 104525, 2020 | 19 | 2020 |
| Approval of biosimilars: a review of unsuccessful regulatory filings AS Rathore, H Chhabra, A Bhargava Expert Opinion on Biological Therapy 21 (1), 19-28, 2021 | 12 | 2021 |
| Regulatory considerations in biosimilars: Latin America region AS Rathore, A Bhargava Preparative Biochemistry & Biotechnology 51 (2), 201-206, 2021 | 10 | 2021 |
| Regulatory considerations in biosimilars: Middle East and Africa regions AS Rathore, A Bhargava Preparative Biochemistry & Biotechnology 51 (8), 731-737, 2021 | 9 | 2021 |
| Regulatory considerations in biosimilars: Asia pacific regions AS Rathore, A Bhargava Preparative Biochemistry & Biotechnology 51 (1), 1-8, 2021 | 6 | 2021 |
| Development and Commercialization of Biosimilars in India: Current Regulatory and Clinical Experience AS Rathore, S Joshi, A Bhargava, N Nupur Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development, 653-674, 2018 | 3 | 2018 |
| Emergency preparedness in a pandemic: Cultural considerations and ethical decision making A Rathore, A Bhargava, MAB Siddique, K Tyson, A Jain, R Khade Pakistan Heart Journal 56 (3), 134-137, 2023 | | 2023 |
| The Current Landscape for developing Biosimilars in India A Bhargava BioProcessing Asia Conference 2018 , Langkawi , Malaysia, 2019 | | 2019 |
| Nutritional supplementation-punctuating constraints in recovery among severely malnourished rural preschool children A Bhargava, SD Gupta The Indian Journal of Pediatrics 50, 29-31, 1983 | | 1983 |
